Furthermore, correctors and potentiatorsdo not work in patients with nonsense mutations that lead to the absenceof the CFTR protein and an estimated 10–15% of CF patientstherefore still have no effective drug treatment. There is therefore still a need to develop compounds thatcan treat the remaining CF patients. This evidence concerns the gene CFTR and cystic fibrosis.